Resveratrol compound was identified to have more inhibitory activity against human oral cancer cell line proteins (KB cells) by this docking study. The docking scores were highest in Beta-actin (-4.51 kcal/mol) followed by Nuclear Factor NF-kappa-B p100 subunit (-3.23 kcal/mol), Cytochrome c1 ( -3.12 kcal/mol), Caspase 3 ( -2.71 kcal/mol) and Caspase 9 (-1.72 kcal/mol). The LogP value and lower hydrogen bond counts, conforming the ability of Resveratrol for binding at the active site of the receptor was determined by in silico method. The potential drug candidate can further be validated in wet lab studies for its proper function.